Exagen inc. completes validation and regulatory submission for new lupus and rheumatoid arthritis biomarkers on the avise® ctd platform

Significant enhancements will equip clinicians with even more diagnostic clarity in the treatment of patients with autoimmune disease significant enhancements will equip clinicians with even more diagnostic clarity in the treatment of patients with autoimmune disease
XGN Ratings Summary
XGN Quant Ranking